# Globus Medical Inc: financial statements, quarterly

GMED · NYSE · CIK 1237831 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gmed.md) · [Financials](/companies/gmed/financials.md) · [Filings](/companies/gmed/filings.md) · [Insiders](/companies/gmed/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gmed/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [384](/filings/0001562762-24-000254.md) | [617 d](/filings/0001628280-26-011209.md) | [607](/filings/0001562762-25-000118.md) | [630](/filings/0001562762-25-000200.md) | [626](/filings/0001237831-25-000031.md) | [657 d](/filings/0001628280-26-011209.md) | [598](/filings/0001628280-26-032290.md) | [745](/filings/0001628280-26-054450.md) | [769](/filings/0001237831-25-000031.md) | [826 d](/filings/0001628280-26-011209.md) | [760](/filings/0001628280-26-032290.md) | [790](/filings/0001628280-26-054450.md) |
| Cost of revenue | $m | [135](/filings/0001562762-24-000254.md) | [265 d](/filings/0001628280-26-011209.md) | [241](/filings/0001562762-25-000118.md) | [260](/filings/0001562762-25-000200.md) | [271](/filings/0001237831-25-000031.md) | [263 d](/filings/0001628280-26-011209.md) | [195](/filings/0001628280-26-032290.md) | [249](/filings/0001628280-26-054450.md) | [253](/filings/0001237831-25-000031.md) | [261 d](/filings/0001628280-26-011209.md) | [234](/filings/0001628280-26-032290.md) | [241](/filings/0001628280-26-054450.md) |
| Gross profit | $m | [248](/filings/0001562762-23-000407.md) | [351 d](/filings/0001562762-24-000032.md) | [365](/filings/0001562762-24-000126.md) | [370](/filings/0001562762-24-000199.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [29.3](/filings/0001562762-24-000254.md) | [52.3 d](/filings/0001628280-26-011209.md) | [57.3](/filings/0001562762-25-000118.md) | [37.7](/filings/0001562762-25-000200.md) | [35.4](/filings/0001237831-25-000031.md) | [33.4 d](/filings/0001628280-26-011209.md) | [33.1](/filings/0001628280-26-032290.md) | [40.0](/filings/0001628280-26-054450.md) | [38.1](/filings/0001237831-25-000031.md) | [36.2 d](/filings/0001628280-26-011209.md) | [36.5](/filings/0001628280-26-032290.md) | [36.3](/filings/0001628280-26-054450.md) |
| Selling, general and administrative | $m | [156](/filings/0001562762-24-000254.md) | [245 d](/filings/0001628280-26-011209.md) | [249](/filings/0001562762-25-000118.md) | [239](/filings/0001562762-25-000200.md) | [240](/filings/0001237831-25-000031.md) | [253 d](/filings/0001628280-26-011209.md) | [243](/filings/0001628280-26-032290.md) | [304](/filings/0001628280-26-054450.md) | [314](/filings/0001237831-25-000031.md) | [318 d](/filings/0001628280-26-011209.md) | [298](/filings/0001628280-26-032290.md) | [287](/filings/0001628280-26-054450.md) |
| Operating income | $m | [0.4](/filings/0001562762-24-000254.md) | [10.1 d](/filings/0001628280-26-011209.md) | [8.0](/filings/0001562762-25-000118.md) | [49.6](/filings/0001562762-25-000200.md) | [48.1](/filings/0001237831-25-000031.md) | [60.3 d](/filings/0001628280-26-011209.md) | [97.0](/filings/0001628280-26-032290.md) | [76.1](/filings/0001628280-26-054450.md) | [137](/filings/0001237831-25-000031.md) | [169 d](/filings/0001628280-26-011209.md) | [150](/filings/0001628280-26-032290.md) | [182](/filings/0001628280-26-054450.md) |
| Income tax | $m | [1.5](/filings/0001562762-24-000254.md) | [10.0 d](/filings/0001628280-26-011209.md) | [(1.4)](/filings/0001562762-25-000118.md) | [15.8](/filings/0001562762-25-000200.md) | [5.2](/filings/0001237831-25-000031.md) | [(1.8) d](/filings/0001628280-26-011209.md) | [28.2](/filings/0001628280-26-032290.md) | [(14.7)](/filings/0001628280-26-054450.md) | [25.0](/filings/0001237831-25-000031.md) | [28.6 d](/filings/0001628280-26-011209.md) | [32.8](/filings/0001628280-26-032290.md) | [38.2](/filings/0001628280-26-054450.md) |
| Net income | $m | [1.0](/filings/0001562762-24-000254.md) | [15.0 d](/filings/0001628280-26-011209.md) | [(7.1)](/filings/0001562762-25-000118.md) | [31.8](/filings/0001562762-25-000200.md) | [51.8](/filings/0001237831-25-000031.md) | [26.5 d](/filings/0001628280-26-011209.md) | [75.5](/filings/0001628280-26-032290.md) | [203](/filings/0001628280-26-054450.md) | [119](/filings/0001237831-25-000031.md) | [141 d](/filings/0001628280-26-011209.md) | [124](/filings/0001628280-26-032290.md) | [152](/filings/0001628280-26-054450.md) |
| Diluted EPS | $ per share | [0.01](/filings/0001562762-24-000254.md) | not reported | [(0.05)](/filings/0001562762-25-000118.md) | [0.23](/filings/0001562762-25-000200.md) | [0.38](/filings/0001237831-25-000031.md) | not reported | [0.54](/filings/0001628280-26-032290.md) | [1.49](/filings/0001628280-26-054450.md) | [0.88](/filings/0001237831-25-000031.md) | not reported | [0.90](/filings/0001628280-26-032290.md) | [1.10](/filings/0001628280-26-054450.md) |
| Basic EPS | $ per share | [0.01](/filings/0001562762-24-000254.md) | not reported | [(0.05)](/filings/0001562762-25-000118.md) | [0.23](/filings/0001562762-25-000200.md) | [0.38](/filings/0001237831-25-000031.md) | not reported | [0.55](/filings/0001628280-26-032290.md) | [1.50](/filings/0001628280-26-054450.md) | [0.88](/filings/0001237831-25-000031.md) | not reported | [0.92](/filings/0001628280-26-032290.md) | [1.12](/filings/0001628280-26-054450.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | [784](/filings/0001628280-26-011209.md) | not reported | not reported | not reported | [526](/filings/0001628280-26-054450.md) | [561](/filings/0001628280-26-032290.md) | [508](/filings/0001628280-26-054450.md) |
| Current assets | $m | [1,917](/filings/0001562762-23-000407.md) | [1,915](/filings/0001562762-25-000026.md) | [1,829](/filings/0001562762-24-000126.md) | [1,924](/filings/0001562762-24-000199.md) | [2,057](/filings/0001562762-24-000254.md) | [2,177](/filings/0001628280-26-011209.md) | [1,710](/filings/0001562762-25-000118.md) | [1,730](/filings/0001562762-25-000200.md) | [1,924](/filings/0001237831-25-000031.md) | [2,126](/filings/0001628280-26-054450.md) | [2,198](/filings/0001628280-26-032290.md) | [2,216](/filings/0001628280-26-054450.md) |
| Total assets | $m | [5,356](/filings/0001562762-23-000407.md) | [5,086](/filings/0001562762-25-000026.md) | [4,944](/filings/0001562762-24-000126.md) | [4,994](/filings/0001562762-24-000199.md) | [5,086](/filings/0001562762-24-000254.md) | [5,252](/filings/0001628280-26-011209.md) | [4,711](/filings/0001562762-25-000118.md) | [4,961](/filings/0001562762-25-000200.md) | [5,096](/filings/0001237831-25-000031.md) | [5,303](/filings/0001628280-26-054450.md) | [5,440](/filings/0001628280-26-032290.md) | [5,488](/filings/0001628280-26-054450.md) |
| Current liabilities | $m | [429](/filings/0001562762-23-000407.md) | [392](/filings/0001562762-25-000026.md) | [786](/filings/0001562762-24-000126.md) | [794](/filings/0001562762-24-000199.md) | [818](/filings/0001562762-24-000254.md) | [856](/filings/0001628280-26-011209.md) | [385](/filings/0001562762-25-000118.md) | [425](/filings/0001562762-25-000200.md) | [466](/filings/0001237831-25-000031.md) | [498](/filings/0001628280-26-054450.md) | [482](/filings/0001628280-26-032290.md) | [479](/filings/0001628280-26-054450.md) |
| Total liabilities | $m | [1,169](/filings/0001562762-23-000407.md) | [1,088](/filings/0001562762-25-000026.md) | [1,021](/filings/0001562762-24-000126.md) | [1,017](/filings/0001562762-24-000199.md) | [1,017](/filings/0001562762-24-000254.md) | [1,074](/filings/0001628280-26-011209.md) | [623](/filings/0001562762-25-000118.md) | [665](/filings/0001562762-25-000200.md) | [697](/filings/0001237831-25-000031.md) | [730](/filings/0001628280-26-054450.md) | [707](/filings/0001628280-26-032290.md) | [720](/filings/0001628280-26-054450.md) |
| Shareholders' equity | $m | [4,187](/filings/0001562762-24-000254.md) | [3,998](/filings/0001628280-26-011209.md) | [3,922](/filings/0001237831-25-000031.md) | [3,976](/filings/0001237831-25-000031.md) | [4,069](/filings/0001237831-25-000031.md) | [4,177](/filings/0001628280-26-054450.md) | [4,088](/filings/0001628280-26-054450.md) | [4,296](/filings/0001628280-26-054450.md) | [4,399](/filings/0001237831-25-000031.md) | [4,573](/filings/0001628280-26-054450.md) | [4,732](/filings/0001628280-26-054450.md) | [4,769](/filings/0001628280-26-054450.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [50.5 d](/filings/0001562762-24-000254.md) | [105 d](/filings/0001628280-26-011209.md) | [52.4](/filings/0001562762-25-000118.md) | [54.3 d](/filings/0001562762-25-000200.md) | [204 d](/filings/0001237831-25-000031.md) | [210 d](/filings/0001628280-26-011209.md) | [177](/filings/0001628280-26-032290.md) | [77.9 d](/filings/0001628280-26-054450.md) | [250 d](/filings/0001237831-25-000031.md) | [249 d](/filings/0001628280-26-011209.md) | [202](/filings/0001628280-26-032290.md) | [210 d](/filings/0001628280-26-054450.md) |
| Capital expenditure | $m | [21.5 d](/filings/0001562762-24-000254.md) | [22.9 d](/filings/0001628280-26-011209.md) | [28.6](/filings/0001562762-25-000118.md) | [27.8 d](/filings/0001562762-25-000200.md) | [42.0 d](/filings/0001237831-25-000031.md) | [17.1 d](/filings/0001628280-26-011209.md) | [36.1](/filings/0001628280-26-032290.md) | [46.6 d](/filings/0001628280-26-054450.md) | [35.8 d](/filings/0001237831-25-000031.md) | [46.2 d](/filings/0001628280-26-011209.md) | [39.6](/filings/0001628280-26-032290.md) | [33.2 d](/filings/0001628280-26-054450.md) |
| Share repurchases | $m | not reported | not reported | [83.3](/filings/0001562762-25-000118.md) | [1.5 d](/filings/0001562762-25-000200.md) | [0.0 d](/filings/0001237831-25-000031.md) | [1.0 d](/filings/0001628280-26-011209.md) | [190](/filings/0001628280-26-032290.md) | [25.0 d](/filings/0001628280-26-054450.md) | [40.0 d](/filings/0001237831-25-000031.md) | [45.0 d](/filings/0001628280-26-011209.md) | [0.0](/filings/0001628280-26-032290.md) | [136 d](/filings/0001628280-26-054450.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [101](/filings/0001562762-23-000407.md) | [102](/filings/0001562762-24-000126.md) | [102](/filings/0001562762-24-000199.md) | [115](/filings/0001562762-24-000254.md) | [135](/filings/0001562762-25-000118.md) | [137](/filings/0001562762-25-000200.md) | [138](/filings/0001237831-25-000031.md) | [140](/filings/0001628280-26-032290.md) | [136](/filings/0001628280-26-054450.md) | [135](/filings/0001237831-25-000031.md) | [138](/filings/0001628280-26-032290.md) | [137](/filings/0001628280-26-054450.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 134,261,914 at 2026-08-04, from the cover of the [10-Q filed 2026-08-06](/filings/0001628280-26-054450.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.